NCT04750889 (RFID) is a clinical trial of RFID tags in Breast Neoplasm Female, sponsored by Centre Jean Perrin.

Who is sponsoring NCT04750889?

NCT04750889 is sponsored by Centre Jean Perrin.

What drugs are being tested in NCT04750889?

Interventions in NCT04750889: RFID tags, Wire localization.

What condition does NCT04750889 study?

NCT04750889 studies Breast Neoplasm Female.

Is NCT04750889 still recruiting?

NCT04750889 is currently completed. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT04750889: RFID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Breast Localization: RFID Tags vs Wire Localization

Completed Last updated 18 June 2023

What this trial tests

trial testing RFID tags in Breast Neoplasm Female in 80 participants. Completed in 24 April 2023.

Timeline

15 May 2021

Primary endpoint
24 April 2023

24 April 2023

Quick facts

Lead sponsor	Centre Jean Perrin
Status	Completed
Study type	OBSERVATIONAL
Enrollment	80
Start date	15 May 2021
Primary completion	24 April 2023
Estimated completion	24 April 2023
Sites	1 location across France

Drugs / interventions tested

RFID tags
Wire localization

Conditions studied

Breast Neoplasm Female — all drugs for Breast Neoplasm Female →

Sponsor

Centre Jean Perrin — full company profile →

Who can join

18 and older, female only, with Breast Neoplasm Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The RFID trial focuses on breast localization in patients with non-palpable breast cancers. It aims to demonstrate the improvement in patient comfort when using the Radio Frequency Identification (RFID) tag and LOCalizer™ device compared to the gold standard device.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire.
Veyssiere H, Dressaire M, Pete R, Pinard C, et al · · 2023 · cited 4× · PMID 37468859 · DOI 10.1186/s12885-023-11190-w
Patient satisfaction with radio-frequency identification (RFID) tag localization compared with wire localization for nonpalpable breast lesions: the RFID trial.
Pete R, Pinard C, Sirodot F, Molnar I, et al · · 2025 · cited 3× · PMID 39844175 · DOI 10.1186/s12885-025-13453-0
Patient Satisfaction with Radio-Frequency Identification (RFID) Tag Localization Compared with Wire Localization for Nonpalpable Breast Lesions: the RFID Trial
PETE R, PINARD C, SIRODOT F, MOLNAR I, et al · · 2024 · DOI 10.21203/rs.3.rs-3848648/v1

Verify or expand the search:

Other recruiting trials for Breast Neoplasm Female

Currently open trials in the same condition.

NCT07465523 — A Novel Approach in the Evaluation of Breast Masses With Doppler US · recruiting
NCT06711523 — Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy · Phase 3 · active not recruiting
NCT05277935 — Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib · NA · recruiting
NCT06234137 — A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrot · NA · recruiting
NCT04812652 — Digitally Distributed Yoga for Women Treated for Breast Cancer · NA · active not recruiting

Other Centre Jean Perrin trials

Trials by the same sponsor.

NCT07361471 — Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovari · NA · recruiting
NCT06512558 — Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery · NA · recruiting
NCT06600802 — Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA- · NA · recruiting
NCT05433077 — Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment · active not recruiting
NCT05157594 — hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04750889 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Jean Perrin
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04750889.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing